293 related articles for article (PubMed ID: 15374956)
21. DNA binding properties of human DNA polymerase eta: implications for fidelity and polymerase switching of translesion synthesis.
Kusumoto R; Masutani C; Shimmyo S; Iwai S; Hanaoka F
Genes Cells; 2004 Dec; 9(12):1139-50. PubMed ID: 15569147
[TBL] [Abstract][Full Text] [Related]
22. Translesion synthesis past estrogen-derived DNA adducts by human DNA polymerases eta and kappa.
Suzuki N; Itoh S; Poon K; Masutani C; Hanaoka F; Ohmori H; Yoshizawa I; Shibutani S
Biochemistry; 2004 May; 43(20):6304-11. PubMed ID: 15147214
[TBL] [Abstract][Full Text] [Related]
23. The N2-ethylguanine and the O6-ethyl- and O6-methylguanine lesions in DNA: contrasting responses from the "bypass" DNA polymerase eta and the replicative DNA polymerase alpha.
Perrino FW; Blans P; Harvey S; Gelhaus SL; McGrath C; Akman SA; Jenkins GS; LaCourse WR; Fishbein JC
Chem Res Toxicol; 2003 Dec; 16(12):1616-23. PubMed ID: 14680376
[TBL] [Abstract][Full Text] [Related]
24. Translesion replication in cisplatin-treated xeroderma pigmentosum variant cells is also caffeine-sensitive: features of the error-prone DNA polymerase(s) involved in UV-mutagenesis.
Yamada K; Takezawa J; Ezaki O
DNA Repair (Amst); 2003 Aug; 2(8):909-24. PubMed ID: 12893087
[TBL] [Abstract][Full Text] [Related]
25. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
26. Interaction with DNA polymerase eta is required for nuclear accumulation of REV1 and suppression of spontaneous mutations in human cells.
Akagi J; Masutani C; Kataoka Y; Kan T; Ohashi E; Mori T; Ohmori H; Hanaoka F
DNA Repair (Amst); 2009 May; 8(5):585-99. PubMed ID: 19157994
[TBL] [Abstract][Full Text] [Related]
27. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta.
Vaisman A; Chaney SG
J Biol Chem; 2000 Apr; 275(17):13017-25. PubMed ID: 10777605
[TBL] [Abstract][Full Text] [Related]
28. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
29. Evidence that in xeroderma pigmentosum variant cells, which lack DNA polymerase eta, DNA polymerase iota causes the very high frequency and unique spectrum of UV-induced mutations.
Wang Y; Woodgate R; McManus TP; Mead S; McCormick JJ; Maher VM
Cancer Res; 2007 Apr; 67(7):3018-26. PubMed ID: 17409408
[TBL] [Abstract][Full Text] [Related]
30. DNA polymerase eta participates in the mutagenic bypass of adducts induced by benzo[a]pyrene diol epoxide in mammalian cells.
Klarer AC; Stallons LJ; Burke TJ; Skaggs RL; McGregor WG
PLoS One; 2012; 7(6):e39596. PubMed ID: 22745795
[TBL] [Abstract][Full Text] [Related]
31. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
32. Dual roles for DNA polymerase eta in homologous DNA recombination and translesion DNA synthesis.
Kawamoto T; Araki K; Sonoda E; Yamashita YM; Harada K; Kikuchi K; Masutani C; Hanaoka F; Nozaki K; Hashimoto N; Takeda S
Mol Cell; 2005 Dec; 20(5):793-9. PubMed ID: 16337602
[TBL] [Abstract][Full Text] [Related]
33. Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy.
Ceppi P; Novello S; Cambieri A; Longo M; Monica V; Lo Iacono M; Giaj-Levra M; Saviozzi S; Volante M; Papotti M; Scagliotti G
Clin Cancer Res; 2009 Feb; 15(3):1039-45. PubMed ID: 19188177
[TBL] [Abstract][Full Text] [Related]
34. Mutation spectra induced by alpha-acetoxytamoxifen-DNA adducts in human DNA repair proficient and deficient (xeroderma pigmentosum complementation group A) cells.
McLuckie KI; Crookston RJ; Gaskell M; Farmer PB; Routledge MN; Martin EA; Brown K
Biochemistry; 2005 Jun; 44(22):8198-205. PubMed ID: 15924439
[TBL] [Abstract][Full Text] [Related]
35. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
Ahmad S
Chem Biodivers; 2010 Mar; 7(3):543-66. PubMed ID: 20232326
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
37. DNA adducts of cisplatin, transplatin and platinum-intercalating drugs.
Leng M; Brabec V
IARC Sci Publ; 1994; (125):339-48. PubMed ID: 7806323
[No Abstract] [Full Text] [Related]
38. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
Zhu G; Myint M; Ang WH; Song L; Lippard SJ
Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
[TBL] [Abstract][Full Text] [Related]
39. A backup role of DNA polymerase kappa in Ig gene hypermutation only takes place in the complete absence of DNA polymerase eta.
Faili A; Stary A; Delbos F; Weller S; Aoufouchi S; Sarasin A; Weill JC; Reynaud CA
J Immunol; 2009 May; 182(10):6353-9. PubMed ID: 19414788
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.
Meynard D; Le Morvan V; Bonnet J; Robert J
Oncol Rep; 2007 May; 17(5):1213-21. PubMed ID: 17390068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
